happy to hear it- I believe the CRADA- Cooperative agreement with the NCI- US Govt- on folfirinox-peg- is Greg's crowning achievement and the basis for a company on it's own- should not be partnered for less than 3 figures.
fezziwig2008 • May 20, 2013 12:53 PM 0users liked this postsusers disliked this posts0Reply
MSN money Calked Baker Bros Geniuses-Upped HALO shr 80 pct last Q!
During Recession MSN called these 2 hedge fund bros. the geniuses of biotech inv- now hold over
3 million shares HALO
Sort: Newest | Oldest | Most Replied Expand all replies
fezziwig2008 • Aug 28, 2013 1:15 PM 0users liked this postsusers disliked this posts0Reply
and So it Began....
fezziwig2008 • Jun 18, 2013 11:16 AM 0users liked this postsusers disliked this posts0Reply
learn from history
fezziwig2008 • May 20, 2013 1:32 PM 0users liked this postsusers disliked this posts0Reply
BAKER BROS ADVISORS LLC 03/31/2013 3,182,251 1,412,475 79.81%
2 Replies to fezziwig2008
fezziwig2008 • May 29, 2013 7:05 AM 0users liked this postsusers disliked this posts0Reply
Jim - I'm in too- this is a good sign
whogo70 • May 20, 2013 1:37 PM
That's what I like about the Baker Brothers. If they like a stock then they buy more shares every qtr.
"Blue Horseshoe Loves Anacott Steel" AND LJPC- The Bakers Penny Stock- they own 10% according to the SEC form 14c I received a few weeks back.
I see HALO partnering or doing a strategic alliance with Celgene on Peg-Gem-Abraxane while hitting the big HR solo on peg-mFolfirinox- whose patent rights it owns outright
One of the most well-known funds, the Baker Brothers, own more than 7 million shares of Halozyme. The fund also added more than 450,000 shares during the most recent quarter. Based on Wednesday’s closing price, that position is worth approximately $77.5 million.
Investors should remember that the Baker Brothers also took early stakes in some of the biggest biotech winners of the past couple years. Some of those investments include Acadia Pharmaceuticals, Pharmacyclics PCYC +2.25%, and Seattle Genetics SGEN -1.1%. When the Baker Brothers put their money up, there is usually a good reason. The fund tends to take positions in biotechs that have upcoming catalysts which leads me to believe that traders are expecting continued trading momentum or a catalyst of some sort.
After the close on Tuesday, December 17th, Halozyme announced that Dr. Helen Torley would replace Gregory Frost as CEO of Halozyme. Dr. Torley has an impressive background, including positions at Amgen AMGN -0.05% and most recently, Onyx Pharmaceuticals. Investors may remember that Amgen acquired Onyx Pharmaceuticals in August 2013 for a purchase price of $10.4 billion. Given Halozyme’s multitude of collaboration agreements with various biopharmaceutical giants, it is possible that traders are speculating on a future buyout that would value Halozyme at $30 per share (twice the current price) at a minimum.
Every Halozyme investor is probably hoping for that buyout announcement which would likely generate a massive return for long-term investors in the company. However, a more likely scenario is that the company will announce a partnership agreement or new trial data before January 17th, 2014 (expiration Friday for options). Given that 19,000 calls that traded resulted in an investment of millions of dollars, the confidence interval is extremely high that Halozyme will be trading much higher than $15 come January.
INVESTING | 12/19/2013 @ 11:59AM Forbes
Traders Make Big Bet On Halozyme Therapeutics
Halozyme Therapeutics has developed a deep and diverse pipeline comprised of proprietary product candidates and collaboration product candidates. The primary product is Hylenex recombinant. This is an approved product which temporarily degrades hyaluronan, a structural protein in the interstitial space. This temporary alteration provides an opportunistic window that allows the delivery of injectable biologics such as monoclonal antibodies, as well as small molecules and fluids. With Halozyme’s enzyme, many pharmaceuticals that would normally be injected intravenously (IV) can be administered subcutaneously (SC). This change in route of delivery may improve patient convenience, enhance pharmacokinetics, boost efficacy, extend the product lifecycle, and reduce cost.
The company’s other product candidates include:
Analog Insulin – PH20: Used for Diabetes and is in Phase 2 development
PEGPH20 – Used for Pancreatic Cancer and is in Phase 2 development
HTI-501 – Used to treat scarring and is in Phase 2 development
Halozyme also has a host of collaboration product candidates which have significant potential to generate milestone revenue going forward. The company intends to use these milestone payments to fund the company’s proprietary research and development efforts.
Now that we’ve covered the company’s product portfolio and overall business strategy, let’s look at the motivation behind the heavy call volume on Wednesday. When it comes to small-cap biotechnology stocks, I really like to look for institutional investment, known as the “smart money.” Each quarter, funds will file their positions and investors can see what the smart guys were up to. - cont'd
the shares bought yesterday were DUE TO the resume of the new CEO- she's not a research scientist- she's a marketer with buy out experience. She's here to do what that implies.
Hi Wallstuff- I didn't go away-just coasting and allowing others to enjoy the board. Honestly, I am glad you asked, because I spent much of the day putting the final touches omn a great family vacation. I will try to keep in touch over the next 10 days, but I'm not sure- there is a time difference involved. Please know that I am long and will be until pegpH20 is universally considered to be the be all and end all of oncology and I can fund the family vacation with 20-30 shares. So when one of the looney birds here say different- you heard it here first- I'll be back before New Years. I will be here through mid day tomorrow to help handle whatever comes our way. Happy Holidays to all!
Happy for you Rock- yes hold on, this is either a long term winner or a B/O- and from thr resume of the new CEO, I'm thinking it's the bird in the hand
um- how MANY yrs is GA 101 delayed for #1 Indication NHL ignoramus? what's the current Rx for NHL? yup MabThera-
BUT that alone doesn't explain Huge Volume in a Co. 68% owned by Institutions.
There's more to this than an Option Buy- it's all in Torley's Resume.
It's also the one thing that gets HALO mentioned on CNBC- with obvious effect- but the main driver here is the New CEO's CV and the task she's been given
I don't think Greg wanted that Job- Helen's better suited for it.
Buying all those Geat Shares of ? For your "European Clients" You are a LUCKY Charm- every time you utter your shortness on Geat Halozyme you lose